PD-1 drugs for Renal Cell Carcinoma

4 tracked PD-1 drugs in the Renal Cell Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Renal Cell Carcinoma page.

4 approved / phase 4

Head-to-head evidence: Nivolumab vs Opdivo Qvantig · Nivolumab vs Pembrolizumab · Nivolumab vs Pembrolizumab berahyaluronidase alfa · Opdivo Qvantig vs Pembrolizumab · Opdivo Qvantig vs Pembrolizumab berahyaluronidase alfa · Pembrolizumab vs Pembrolizumab berahyaluronidase alfa

The roster

← all PD-1 drugs